Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D3 Maintenance in Multiple Myeloma Post-Transplant
NCT05846880Phase 1Recruiting
- Start
- Dec 2024
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vitamin d in multiple myeloma (MM) (2 arms). Primary endpoint: Lymphocyte subset analysis at 120 days. Started Dec 2024; status: recruiting.
02
Drugs
vitamin d
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05846880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846880.